Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO) revealed on Wednesday that the US Food and Drug Administration (FDA) has issued a Complete Response Letter relating to the Biologics License Application for once-weekly basal insulin icodec for the treatment of diabetes mellitus.
The FDA requested additional information concerning the manufacturing process and the type 1 diabetes indication.
Novo Nordisk said that it will work closely with the FDA to address the requests but does not expect to be able to do so in 2024.
Insulin icodec is approved for both type 1 and type 2 diabetes in the European Union, Canada, Australia, Japan and Switzerland, and for type 2 diabetes in China.
CMIC agrees agentic AI partnership with Bluenote
Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment
Precision BioSciences receives FDA Fast Track designation for PBGENE-DMD
Egetis receives US notice of allowance for MCT8 deficiency composition patent
Ipsen withdraws tazverik across all markets following safety concerns in lymphoma trial
Foresee Pharmaceuticals receives positive CHMP opinion for CAMCEVI 21 mg
Great Novel Therapeutics' GNTbm-38 approved by US FDA for Phase I trial
Johnson & Johnson reports US FDA approval of TECVAYLI plus DARZALEX FASPRO for RRMM
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Esperion to acquire Corstasis, expanding cardiovascular portfolio
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117
BD receives FDA clearance for Surgiphor 1000mL irrigation system